1 min read
Add as a preferred source on Google

FDA Grants Priority Review to AstraZeneca’s Gastric Cancer Application

The biologics license application seeks U.S. approval of sonesitatug vedotin, also known as Sone-Ve.

A glass vial sits beside a microscope in an oncology research lab / TokenPost.ai
A glass vial sits beside a microscope in an oncology research lab / TokenPost.ai

AstraZeneca’s application for its gastric cancer therapy sonesitatug vedotin received priority review from the U.S. Food and Drug Administration on Nov. 19, advancing the company’s request for U.S. approval.

The agency accepted the biologics license application for sonesitatug vedotin, also known as Sone-Ve, and issued priority review for the filing. The application seeks approval to use the therapy against gastric cancer.

Riza Dagoc

Riza Dagoc reports on regulation, investing and the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…